MX2023002321A - Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. - Google Patents
Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.Info
- Publication number
- MX2023002321A MX2023002321A MX2023002321A MX2023002321A MX2023002321A MX 2023002321 A MX2023002321 A MX 2023002321A MX 2023002321 A MX2023002321 A MX 2023002321A MX 2023002321 A MX2023002321 A MX 2023002321A MX 2023002321 A MX2023002321 A MX 2023002321A
- Authority
- MX
- Mexico
- Prior art keywords
- hair loss
- deuterated
- treatment
- loss disorders
- jak inhibitors
- Prior art date
Links
- 201000004384 Alopecia Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000024963 hair loss Diseases 0.000 title abstract 2
- 230000003676 hair loss Effects 0.000 title abstract 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 abstract 1
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 abstract 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 abstract 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describe un método para tratar trastornos de pérdida del cabello en un sujeto que se tratan de manera beneficiosa administrando un inhibidor de JAK1 y/o JAK2. El método comprende administrar al sujeto una cantidad en el intervalo de aproximadamente 4 mg a aproximadamente 50 mg del Compuesto (I): (ver Fórmula) Compuesto (1) o una sal farmacéuticamente aceptable de éste. Esta invención también proporciona composiciones que comprende el Compuesto (I) y el uso de tales composiciones en los métodos descritos.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662331827P | 2016-05-04 | 2016-05-04 | |
US201662338869P | 2016-05-19 | 2016-05-19 | |
US201662418774P | 2016-11-07 | 2016-11-07 | |
US201662419237P | 2016-11-08 | 2016-11-08 | |
US201662434404P | 2016-12-14 | 2016-12-14 | |
US201762466358P | 2017-03-02 | 2017-03-02 | |
US201762492758P | 2017-05-01 | 2017-05-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023002321A true MX2023002321A (es) | 2023-03-22 |
Family
ID=60203616
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018013347A MX2018013347A (es) | 2016-05-04 | 2017-05-04 | Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
MX2021014175A MX2021014175A (es) | 2016-05-04 | 2018-10-31 | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
MX2023002323A MX2023002323A (es) | 2016-05-04 | 2018-10-31 | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
MX2023002321A MX2023002321A (es) | 2016-05-04 | 2018-10-31 | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
MX2023002325A MX2023002325A (es) | 2016-05-04 | 2018-10-31 | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
MX2023002324A MX2023002324A (es) | 2016-05-04 | 2018-10-31 | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018013347A MX2018013347A (es) | 2016-05-04 | 2017-05-04 | Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
MX2021014175A MX2021014175A (es) | 2016-05-04 | 2018-10-31 | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
MX2023002323A MX2023002323A (es) | 2016-05-04 | 2018-10-31 | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023002325A MX2023002325A (es) | 2016-05-04 | 2018-10-31 | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
MX2023002324A MX2023002324A (es) | 2016-05-04 | 2018-10-31 | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. |
Country Status (10)
Country | Link |
---|---|
US (2) | US10561659B2 (es) |
EP (1) | EP3452039A4 (es) |
JP (2) | JP7145080B2 (es) |
KR (2) | KR20230086814A (es) |
CN (1) | CN109069493A (es) |
AU (2) | AU2017261286B2 (es) |
BR (1) | BR112018072339A2 (es) |
CA (1) | CA3022519A1 (es) |
MX (6) | MX2018013347A (es) |
WO (1) | WO2017192905A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021236139A1 (en) | 2020-05-21 | 2021-11-25 | Concert Pharmaceuticals, Inc. | Novel deuterated jak inhibitor and uses thereof |
US20230390292A1 (en) | 2020-10-28 | 2023-12-07 | Sun Pharmaceutical Industries, Inc. | Regimens for the treatment of hair loss disorders with deuterated jak inhibitors |
CN112402615A (zh) * | 2020-11-11 | 2021-02-26 | 长沙晶易医药科技有限公司 | 一种用于治疗斑秃的复方外用制剂及其制备方法 |
WO2023018904A1 (en) | 2021-08-11 | 2023-02-16 | Concert Pharmaceuticals, Inc. | Treatment of hair loss disorders with deuterated jak inhibitors |
WO2023018954A1 (en) | 2021-08-12 | 2023-02-16 | Concert Pharmaceuticals, Inc. | Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors |
WO2023215520A1 (en) | 2022-05-04 | 2023-11-09 | Sun Pharmaceutical Industries, Inc. | Dosage regimens for treatment with deuterated jak inhibitors |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
WO2002089835A2 (en) | 2001-05-03 | 2002-11-14 | F. Hoffmann-La Roche Ag | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
JP2008514706A (ja) | 2004-09-29 | 2008-05-08 | コーディス・コーポレイション | 安定非晶質ラパマイシン様化合物の薬学的投与形態 |
HUE030235T2 (en) | 2005-12-13 | 2017-04-28 | Incyte Holdings Corp | Heteroaryl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors |
EP3708564A1 (en) | 2005-12-28 | 2020-09-16 | Vertex Pharmaceuticals Incorporated | A solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
PL2635299T3 (pl) * | 2010-11-02 | 2020-03-31 | The Trustees Of Columbia University In The City Of New York | Sposoby leczenia zaburzeń utraty włosów |
ES2694681T3 (es) | 2012-03-29 | 2018-12-26 | The Trustees Of Columbia University In The City Of New York | Métodos para tratar trastornos de pérdida capilar |
US20150197525A1 (en) | 2012-06-15 | 2015-07-16 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of ruxolitinib |
AU2013296627C9 (en) * | 2012-07-30 | 2018-03-22 | Concert Pharmaceuticals, Inc. | Deuterated ibrutinib |
KR20220162825A (ko) | 2012-11-15 | 2022-12-08 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
JP6367545B2 (ja) | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
CN104725380B (zh) * | 2013-12-18 | 2019-06-28 | 康塞特医药品有限公司 | 卢索替尼的氘代衍生物 |
EA201691582A1 (ru) | 2014-02-07 | 2017-01-30 | Оспекс Фармасьютикалз, Инк. | Новые фармацевтические препараты |
-
2017
- 2017-05-04 JP JP2018557837A patent/JP7145080B2/ja active Active
- 2017-05-04 WO PCT/US2017/031142 patent/WO2017192905A1/en active Application Filing
- 2017-05-04 KR KR1020237019001A patent/KR20230086814A/ko not_active Application Discontinuation
- 2017-05-04 CN CN201780027427.2A patent/CN109069493A/zh active Pending
- 2017-05-04 KR KR1020187034867A patent/KR20190003711A/ko active Application Filing
- 2017-05-04 AU AU2017261286A patent/AU2017261286B2/en active Active
- 2017-05-04 EP EP17793380.1A patent/EP3452039A4/en active Pending
- 2017-05-04 US US16/098,338 patent/US10561659B2/en active Active
- 2017-05-04 CA CA3022519A patent/CA3022519A1/en active Pending
- 2017-05-04 BR BR112018072339-8A patent/BR112018072339A2/pt active Search and Examination
- 2017-05-04 MX MX2018013347A patent/MX2018013347A/es unknown
-
2018
- 2018-10-31 MX MX2021014175A patent/MX2021014175A/es unknown
- 2018-10-31 MX MX2023002323A patent/MX2023002323A/es unknown
- 2018-10-31 MX MX2023002321A patent/MX2023002321A/es unknown
- 2018-10-31 MX MX2023002325A patent/MX2023002325A/es unknown
- 2018-10-31 MX MX2023002324A patent/MX2023002324A/es unknown
-
2019
- 2019-12-05 US US16/704,402 patent/US20200222408A1/en active Pending
-
2022
- 2022-09-16 JP JP2022147751A patent/JP2022171838A/ja active Pending
-
2023
- 2023-02-24 AU AU2023201112A patent/AU2023201112A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022171838A (ja) | 2022-11-11 |
JP2019516684A (ja) | 2019-06-20 |
JP7145080B2 (ja) | 2022-09-30 |
CA3022519A1 (en) | 2017-11-09 |
AU2017261286A1 (en) | 2018-11-22 |
MX2023002325A (es) | 2023-03-22 |
AU2017261286B2 (en) | 2023-03-23 |
US10561659B2 (en) | 2020-02-18 |
MX2018013347A (es) | 2019-09-02 |
MX2023002323A (es) | 2023-03-22 |
MX2021014175A (es) | 2022-01-04 |
EP3452039A4 (en) | 2019-12-25 |
AU2023201112A1 (en) | 2023-03-30 |
MX2023002324A (es) | 2023-03-22 |
BR112018072339A2 (pt) | 2019-02-19 |
EP3452039A1 (en) | 2019-03-13 |
KR20190003711A (ko) | 2019-01-09 |
US20190160068A1 (en) | 2019-05-30 |
WO2017192905A1 (en) | 2017-11-09 |
US20200222408A1 (en) | 2020-07-16 |
KR20230086814A (ko) | 2023-06-15 |
CN109069493A (zh) | 2018-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023002325A (es) | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. | |
MX2018003331A (es) | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. | |
EA202190630A1 (ru) | Способы комбинированной терапии | |
PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
MX2023004593A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
EA202092343A1 (ru) | Лечение гнойного гидраденита с использованием ингибиторов jak | |
MX2016008201A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
MD4800C1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
MX2021002521A (es) | Dimetilaminoazetidinaminas como inhibidores de jak. | |
MX2021012501A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
MX2019013561A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
MX2021007260A (es) | Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales. | |
MX2021006156A (es) | Compuestos utiles en la terapia para el vih. | |
MX2021006619A (es) | Inhibidores de la tirosina quinasa, composiciones y sus metodos. | |
MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
MX2021013602A (es) | Inhibidores de jak. | |
MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
EA201892098A1 (ru) | Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения | |
MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
MX2021011986A (es) | Metodos de tratamiento de dolor neuropatico. | |
MX2023005027A (es) | Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados. | |
PH12020551620A1 (en) | Compositions for preventing or treating dry eye | |
MX2022001702A (es) | Inhibidores de jak. |